#1 Clinical Trials Search in Europe

Ammonium Chloride Bp

This article discusses recent clinical trials investigating the use of Ammonium Chloride BP, often combined with Diphenhydramine Hydrochloride BP, in the treatment of various types of lymphoma. These trials aim to evaluate the safety, efficacy, and potential benefits of this drug combination for patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The studies focus on different aspects of treatment, including dosage, administration methods, and combination with other therapies.

Table of Contents

What is Ammonium Chloride BP?

Ammonium Chloride BP is a medication that is often used in combination with other drugs, particularly in the treatment of various types of lymphoma[1]. The “BP” in its name stands for “British Pharmacopoeia,” which indicates that it meets specific quality standards. This drug is also known by its chemical name, NH4Cl.

Medical Uses

While Ammonium Chloride BP itself is not a primary treatment for lymphoma, it is often used as part of a combination therapy or as a supportive medication. Its main uses in the context of lymphoma treatment include:

  • Supportive Care: It may be used to manage certain side effects of cancer treatments or to prepare patients for specific therapies[2].
  • Combination Therapy: Ammonium Chloride BP is frequently combined with other medications, such as Diphenhydramine Hydrochloride BP, to enhance overall treatment effectiveness[3].

It’s important to note that this medication is not a direct treatment for lymphoma itself, but rather plays a supportive role in overall cancer care.

Administration

Ammonium Chloride BP can be administered in various ways, depending on the specific treatment plan and the patient’s needs. Common routes of administration include:

  • Oral: It may be given as a tablet or solution to be taken by mouth[2].
  • Intravenous (IV): In some cases, it might be administered directly into the bloodstream through an IV line[3].

The dosage and frequency of administration will be determined by your healthcare provider based on your individual medical condition and treatment plan.

Potential Side Effects

As with any medication, Ammonium Chloride BP may cause side effects. It’s important to discuss potential side effects with your healthcare provider. Some possible side effects may include:

  • Nausea or vomiting
  • Stomach discomfort
  • Changes in electrolyte balance

If you experience any severe or persistent side effects, contact your healthcare provider immediately.

Precautions and Considerations

When using Ammonium Chloride BP, there are several important considerations to keep in mind:

  • Medical History: Inform your doctor about your complete medical history, especially if you have kidney problems or liver disease[1].
  • Pregnancy and Breastfeeding: If you are pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks and benefits with your healthcare provider[3].
  • Other Medications: Tell your doctor about all medications you are taking, including over-the-counter drugs and supplements, to avoid potential interactions.
  • Follow-up Care: Regular check-ups and blood tests may be necessary to monitor your response to treatment and manage any side effects.

Remember, Ammonium Chloride BP is typically used as part of a comprehensive treatment plan. Always follow your healthcare provider’s instructions carefully and report any concerns or unusual symptoms promptly.

Aspect Details
Drug Combination Ammonium Chloride BP and Diphenhydramine Hydrochloride BP
Lymphoma Types Studied Hodgkin lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma
Patient Population Adults with relapsed or refractory disease
Administration Methods Intravenous infusion and oral routes
Primary Objectives Safety, efficacy, maximum tolerated dose, pharmacokinetics, anti-tumor activity
Secondary Objectives Quality of life impact, immune response, duration of response
Key Endpoints Objective response rate, progression-free survival, overall survival, adverse events
Monitoring Focus Vital signs, laboratory results, treatment-emergent adverse events, anti-drug antibodies

FAQ

  • What types of lymphoma are being studied in these clinical trials? The clinical trials are studying various types of lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. These trials focus on patients with relapsed or refractory disease, meaning their cancer has returned or did not respond to previous treatments.
  • How is Ammonium Chloride BP being administered in these trials? Ammonium Chloride BP is being administered in combination with Diphenhydramine Hydrochloride BP. The administration methods vary between trials, but they include intravenous infusion and oral routes. Some trials are exploring different dosing schedules and amounts to determine the most effective and safe approach.
  • What are the main objectives of these clinical trials? The main objectives of these trials include evaluating the safety and efficacy of the drug combination, determining the maximum tolerated dose, assessing the drug's pharmacokinetic properties, and measuring the anti-tumor activity. Some trials also aim to evaluate the impact on patients' quality of life and immune response to the treatment.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary between trials but generally include adult patients (18 years and older) with confirmed diagnoses of specific lymphoma types. Patients must have relapsed or refractory disease and have undergone previous treatments. Some trials have specific requirements regarding the number of prior therapies and the patient's overall health status.
  • What are some potential side effects being monitored in these trials? The trials are closely monitoring for adverse events and side effects. Common areas of focus include changes in vital signs, clinical laboratory test results, and the occurrence of treatment-emergent adverse events. Some trials are also assessing the development of anti-drug antibodies and cytokine release syndrome. Patients are regularly evaluated for any signs of toxicity or other health concerns throughout the study period.

Ongoing Clinical Trials on Ammonium Chloride Bp

  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France Germany Italy The Netherlands

Glossary

  • Relapsed/Refractory (R/R): This refers to cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • Mantle Cell Lymphoma (MCL): A type of non-Hodgkin lymphoma that develops in the outer edge of a lymph node called the mantle zone.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Cytokine Release Syndrome (CRS): A condition that can occur after some types of immunotherapy, causing symptoms such as fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing.
  • Anti-Drug Antibodies (ADAs): Antibodies that develop in response to a therapeutic drug, potentially affecting its efficacy or safety.

References

  1. http://clinicaltrials.eu/trial/study-comparing-glofitamab-alone-to-bendamustine-with-rituximab-or-lenalidomide-with-rituximab-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gen3017-for-patients-with-relapsed-or-refractory-hodgkin-and-non-hodgkin-lymphoma/
  3. http://clinicaltrials.eu/trial/study-of-axicabtagene-ciloleucel-for-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma/